An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3K* Inhibitor, GS-9820
- Conditions
- CLLChronic Lymphatic Leukemia10024324
- Registration Number
- NL-OMON43418
- Lead Sponsor
- Gilead Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
1) Receiving GS-9820 in Study GS-US-315-0102 with objective evidence of clinical benefit defined as at least stable disease on imaging assessed by the IRC at the time of Study GS-US-315-0102 closure;2) For female subjects of childbearing potential, willingness to use a protocol recommended method of contraception during heterosexual intercourse from the signing of informed consent throughout the study treatment period and up to 30 days from the last dose of idelalisib;3) For male subjects of reproductive potential having intercourse with females of childbearing potential, willing to use a protocol recommended method of contraception during heterosexual intercourse and to refrain from sperm donation throughout the study treatment period and for 90 days following discontinuation of idelalisib;4) Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions, including mandatory prophylaxis for Pneumocystis jirovecci pneumonia (PJP). Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.;5) Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of their disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, possible side effects, potential risks and discomforts, and other pertinent aspects of study participation.
1) Known hypersensitivity or intolerance to any of the active substances or excipients in the formulation of idelalisib.;2) Toxicities that would preclude initiating therapy with idelalisib prior to enrolment (eg history of drug-induced pneumonitis, ongoing inflammatory bowel disease);3) Concurrent participation in another therapeutic clinical trial.;4) Pregnant or breastfeeding.;5) Ongoing infection, treatment, or profylaxis for CMV within the past 28 days.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>There are no primary endpoints of this study.</p><br>
- Secondary Outcome Measures
Name Time Method <p>There are no secondary endpoints of this study</p><br>